World Journal of
Pharmaceutical and Life Sciences

CLINICAL FINDINGS, DIAGNOSIS AND TREATMENT STRATEGIES OF MUCOPOLYSACCHARIDOSIS TYPE I

Dr. Sikander Ali*, Muhammad Waqar and Arzoo Afzal

ABSTRACT

Mucopolysaccharidosis type I (MPS I) is a disease caused by the deficiency of alpha-L-iduronidase (a lysosomal enzyme), as a result of which glycosaminoglycans accumulate resulting in progressive multi-organ dysfunction. Cases of MPS I are classified into severe and attenuated forms. Hurler syndrome is the severe form and Hurler-Scheie and Scheie syndromes are the attenuated forms. It has broad clinical spectrum which differs in both severe and attenuated phenotypes. It is a rare disease. One case is seen in one lac births. Its diagnosis is established by clinical and laboratory findings, molecular gene testing and detecting the deficiency of alpha-L-iduronidase. Two treatment options i.e. hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) are available. Disease management of MPS I is not consistent because of heterogenous phenotypes, few therapeutic options and rarity. Information about the history of MPS I may aid in the management of affected individuals.

[Full Text Article]   [Download Certificate]